An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease

Sandborn, William J.; Hanauer, Stephen; Loftus, Edward V.; Tremaine, William J.; Kane, Sunanda; Cohen, Russell; Hanson, Karen; Johnson, Therese; Schmitt, Debra; Jeche, Resa
October 2004
American Journal of Gastroenterology;Oct2004, Vol. 99 Issue 10, p1984
Academic Journal
BACKGROUND: We assessed the tolerability and clinical benefit of adalimumab, a human antibody to tumor necrosis factor (TNF), in patients with Crohn's disease who had previously received and responded to the chimeric anti-TNF antibody infliximab, but who no longer had a sustained response and/or tolerance to infliximab.METHODS: A total of 24 patients with Crohn's disease who had lost responsiveness or developed intolerance (acute or delayed infusion reactions) to infliximab were enrolled in a 12-wk uncontrolled trial and treated with subcutaneous adalimumab 80 mg at week 0 and then 40 mg every other week starting at week 2. After week 4, the dose could be escalated to 40 mg weekly in patients who did not achieve clinical remission, complete fistula closure, and complete steroid withdrawal. Outcome measures included the ability to tolerate adalimumab and clinical remission (defined as a Crohn's disease activity index (CDAI) score≤150 points) and clinical response (defined as a decrease in the CDAI)≥100 points) in patients who had a baseline CDAI score≥220.RESULTS: None of the patients experienced acute or delayed hypersensitivity reactions during treatment with adalimumab (including 14 who previously experienced treatment-limiting acute hypersensitivity reactions and 6 who previously experienced delayed hypersensitivity reactions with infliximab). Of 17 patients with baseline CDAI scores≥220: clinical remission occurred at weeks 4 and 12 in 2 (12%) and 5 (29%), respectively; and clinical response occurred in 7 (41%) and 10 (59%), respectively. Nineteen patients (79%) escalated their dose during weeks 4–6.CONCLUSIONS: Adalimumab is well tolerated and appears to be a clinically beneficial option for patients with Crohn's disease who have previously lost their response to, or cannot tolerate infliximab.


Related Articles

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • Inflixmab as a possible treatment for the hemorrhagic type of Crohn’s disease. Tsujikawa, Tomoyuki; Nezu, Riichiro; Andoh, Akira; Saotome, Takao; Araki, Yoshio; Ishizuka, Yoshiyuki; Sasaki, Masaya; Koyama, Shigeki; Fujiyama, Yoshihide // Journal of Gastroenterology;2004, Vol. 39 Issue 3, p284 

    Acute lower gastrointestinal bleeding is a rare complication of Crohn’s disease (CD). Although anti-tumor necrosis factor-Α (TNF-Α, infliximab) therapy has been established for patients with inflammatory and fistulous CD, there has been little evidence on whether infliximab is...

  • Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease. Viola, Franca; Civitelli, Fortunata; Di Nardo, Giovanni; Barbato, Maria Beatrice; Borrelli, Osvaldo; Oliva, Salvatore; Conte, Francesca; Cucchiara, Salvatore // American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2566 

    OBJECTIVES:The use of tumor necrosis factor-alpha (TNF-α) antagonists has changed the therapeutic strategy for Crohn's disease (CD). Adalimumab (ADA), a fully human anti-TNF-α monoclonal antibody, is an effective therapy for patients with CD, both naive patients and those intolerant or...

  • Infliximab.  // Reactions Weekly;7/22/2006, Issue 1111, p14 

    The article presents a case study of a 40-year-old woman who was diagnosed with reactivation histoplasmosis while being treated with infliximab for Crohn's disease.

  • The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.  // Inflammatory Bowel Disease Monitor;2010, Vol. 10 Issue 4, p133 

    The efficacy and tolerability of a third anti-tumor necrosis factor (anti-TNF) agent after failure of and/or intolerance to two previous anti-TNF agents in Crohn's disease patients was evaluated in this study. Overall, 67 patients received a third anti-TNF agent. By 9 months, 46% of patients...

  • Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody. Mori, Shunsuke; Imamura, Fumiya; Kiyofuji, Chikage; Sugimoto, Mineharu // Modern Rheumatology;Aug2006, Vol. 16 Issue 4, p251 

    Infliximab, an anti-tumor necrosis factor (TNF)-α antibody, was introduced to a 66-year-old woman with methotrexate (MTX)-resistant rheumatoid arthritis (RA). Although the TNF-blocking therapy was successful, she developed noninfectious interstitial pneumonia (IP) after a second infusion of...

  • NICE recommends treatments for Crohn's disease.  // Practice Nurse;5/28/2010, Vol. 39 Issue 10, p6 

    The article presents the recommendation by the British National Institute for Health and Clinical Excellence (NICE) of infliximab and adalimumab as treatments for patients with Crohn's disease.

  • Incessant pericardial effusion in a 9 year old male responding to infliximab. Walsh, Rowan F.; Chowdhury, Devyani // Cardiology in the Young;Aug2009, Vol. 19 Issue 4, p413 

    Recurrent idiopathic pericardial effusion can be a challenging medical problem. Multiple medical interventions may yield minimal improvement. We describe a patient with an incessant pericardial effusion that responded to infliximab. The use of infliximab should be considered in the management of...

  • Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Vermeire, Severine; Noman, Maja; Van Assche, Gert; Baert, Filip; D'Haens, Geert; Rutgeerts, Paul // Gut;Sep2007, Vol. 56 Issue 9, p1226 

    Background: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation. Aims...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics